- **Actinium Pharmaceuticals (ATNM)** announced **superior preclinical efficacy** of its lead solid tumor program, **ATNM-400**, in non-small cell lung cancer (NSCLC).  **[1388320_20251027NY07029:0]** 
- ATNM-400 demonstrated **3-5 times greater tumor growth inhibition** as a monotherapy compared to current standard-of-care EGFR-mutant NSCLC therapies, including osimertinib, Dato-DXd, and amivantamab.  **[1388320_20251027NY07029:0]** 
- In combination with osimertinib, ATNM-400 achieved **complete tumor regression in 100% of tumor-bearing animals**, indicating synergistic activity.  **[1388320_20251027NY07029:0]** **[1388320_20251027NY07029:1]** 
- The company highlights the **multi-tumor potential** of ATNM-400, which is also being developed for prostate cancer, and aims to address the significant unmet need in NSCLC where existing therapies generated approximately **$7 billion in sales in 2024** but face resistance issues.  **[1388320_20251027NY07029:0]** **[1388320_20251027NY07029:1]** **[1388320_20251027NY07029:2]**